These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 21278045)

  • 1. To screen or not to screen: ongoing debate in the early detection of prostate cancer.
    Marroquin JM
    Clin J Oncol Nurs; 2011 Feb; 15(1):97-8. PubMed ID: 21278045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for prostate cancer with the prostate-specific antigen test: are patients making informed decisions?
    O'Dell KJ; Volk RJ; Cass AR; Spann SJ
    J Fam Pract; 1999 Sep; 48(9):682-8. PubMed ID: 10498074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PSA and other tissue kallikreins for prostate cancer detection.
    Stephan C; Jung K; Lein M; Diamandis EP
    Eur J Cancer; 2007 Sep; 43(13):1918-26. PubMed ID: 17689069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
    Fitzpatrick JM; Banu E; Oudard S
    BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.
    Morote J; Raventós CX; Lorente JA; Lopez-Pacios MA; Encabo G; de Torres I; Andreu J
    J Urol; 1997 Aug; 158(2):502-4. PubMed ID: 9224333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from high-risk prostate cancer families.
    Matikainen MP; Schleutker J; Mörsky P; Kallioniemi OP; Tammela TL
    Clin Cancer Res; 1999 Jun; 5(6):1275-9. PubMed ID: 10389909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay.
    Ellis WJ; Vessella RL; Noteboom JL; Lange PH; Wolfert RL; Rittenhouse HG
    Urology; 1997 Oct; 50(4):573-9. PubMed ID: 9338734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
    Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
    Andriole GL; Marberger M; Roehrborn CG
    J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ; Roobol DW; Schröder FH
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen testing to screen for prostate cancer.
    Budenholzer BR
    J Fam Pract; 1995 Sep; 41(3):270-8. PubMed ID: 7544400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
    Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer.
    Schröder FH; Roobol MJ
    Curr Opin Urol; 2009 May; 19(3):227-31. PubMed ID: 19357513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen in clinical practice.
    Loeb S; Catalona WJ
    Cancer Lett; 2007 Apr; 249(1):30-9. PubMed ID: 17258389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer detection in men with a 'normal' total prostate-specific antigen (PSA) level using percentage free PSA: a prospective screening study.
    Rowe EW; Laniado ME; Walker MM; Patel A
    BJU Int; 2005 Jun; 95(9):1249-52. PubMed ID: 15892810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ
    J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revised status of PSA testing in the early detection and treatment of prostate cancer.
    Lamb DS; Delahunt B; Nacey JN
    N Z Med J; 2011 Nov; 124(1345):13-5. PubMed ID: 22072161
    [No Abstract]   [Full Text] [Related]  

  • 19. Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA?
    Connolly D; Black A; Murray LJ; Nambirajan T; Keane PF; Gavin A
    Prostate Cancer Prostatic Dis; 2009; 12(1):47-51. PubMed ID: 18762815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer. When to offer screening in the primary care setting.
    Gambert SR
    Geriatrics; 2001 Jan; 56(1):22-6, 29-31. PubMed ID: 11196336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.